Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-18T03:18:10.373Z Has data issue: false hasContentIssue false

Chapter 17 - Myelodysplastic/Myeloproliferative Neoplasms

from Section IV - Precursor Hematopoietic Neoplasms and Related Neoplasms

Published online by Cambridge University Press:  25 November 2023

By
Kristian T. Schafernak ,
Rachel A. Mariani ,
Nicole Arva ,
Jeffrey Jacobsen  and
Katherine R. Calvo
Edited by
Silvia Tse Bunting ,
Xiayuan Liang ,
Michele E. Paessler  and
Satheesh Chonat
Silvia Tse Bunting
Affiliation:
Cleveland Clinic Florida Weston
Xiayuan Liang
Affiliation:
University of Colorado
Michele E. Paessler
Affiliation:
University of Pennsylvania School of Medicine
Satheesh Chonat
Affiliation:
Emory University, Atlanta
Get access

Summary

Myelodysplastic/myeloproliferative neoplasm (MDS/MPNs) constitute a group of clonal hematopoietic disorders with hybrid features; those of a myeloproliferative neoplasm (MPN) include bone marrow hypercellularity due to proliferation of one or more of the myeloid (as opposed to lymphoid) lineages with effective hematopoiesis, leading to a peripheral “cytosis” or “cytoses.” At the same time, these disorders show variable morphologic or functional dysplasia with ineffective hematopoiesis, resulting in cytopenia(s), findings more characteristic of myelodysplastic syndrome (MDS). The blast percentage is always less than 20, though sometimes transformation to acute myeloid leukemia (AML) occurs.

Type
Chapter
Information
Atlas of Pediatric Hematopathology , pp. 186 - 197
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017.Google Scholar
Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.Google Scholar
Friedman, JM. Neurofibromatosis 1. Adam, MP, Ardinger, HH, Pagon, RA, et al., eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. www.ncbi.nlm.nih.gov/books/NBK1109” www.ncbi.nlm.nih.gov/books/NBK1109.Google Scholar
Denayer, E, Peeters, H, Sevenants, L, Derbent, M, Fryns, JP, Legius, E. NRAS mutations in Noonan syndrome. Mol Syndromol. 2012; 3: 34–8.CrossRefGoogle ScholarPubMed
Bhambhani, V, Muenke, M. Noonan syndrome. Am Fam Physician. 2014; 89: 37–43.Google ScholarPubMed
Digilio, MC, Marino, B. Clinical manifestations of Noonan syndrome. Images Paediatr Cardiol. 2001; 3: 19–30.Google ScholarPubMed
Calvo, KR, Price, S, Braylan, RC, Oliveira, JB, Lenardo, M, Fleisher, TA, et al. JMML and RALD (RAS-associated autoimmune leukoproliferative disorder): Common genetic etiology yet clinically distinct entities. Blood. 2015; 125: 2753–8.CrossRefGoogle ScholarPubMed
Ganapathi, KA, Schafernak, KT, Rao, VK, Calvo, KR. Pediatric myelodysplastic/myeloproliferative neoplasms and related diseases. J Hematopathol. 2015; 8: 159–67.CrossRefGoogle Scholar
Lanzarotti, N, Bruneau, J, Trinquand, A, Stoltzenberg, MC, Neven, B, Fregeac, J, et al. RAS-associated lymphoproliferative disease evolves into severe juvenile myelo-monocytic leukemia. Blood. 2014; 123: 1960–3.CrossRefGoogle ScholarPubMed
Niemeyer, CM, Flotho, C. Juvenile myelomonocytic leukemia: Who’s the driver at the wheel? Blood. 2019; 133: 1060–70.CrossRefGoogle ScholarPubMed
Röttgers, S, Gombert, M, Teigler-Schlegel, A, Busch, K, Gamerdinger, U, Slany, R, et al. ALK fusion genes in children with atypical myeloproliferative leukemia. Leukemia. 2010; 24: 1197–200.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×